Patient P-01765
Synthetic patientNBL-101 · Day 115 · 35–44 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Stable
GI state
Stable
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
92%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 50 SC-12 recommended — Supportive Compound SC-12
- Day 51 Patient accepted — Started SC-12 in the companion
- Day 57 GI symptom burden −22% vs expected — Supportive Compound SC-12
- Day 63 Tolerance state changed — Unstable → Improving
- Day 72 ME-01 recommended — Monitoring Escalation ME-01
- Day 73 Patient accepted — Started ME-01 in the companion
- Day 76 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 48.
Primary contributors, last 14 days
- Inflammatory activity-6
- GI instability+4
- Treatment adherence-4
- Nutritional resilience-3
- Toxicity-2
What helped?
- Supportive Compound SC-12Day 50Result: symptom burden −22%
- Monitoring Escalation ME-01Day 72Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion56.4/100
improving · -8.0 vs previous 14 d
Toxicity
Blood44/100
stable · -1.5 vs previous 14 d
Sleep quality
Wearable24.1/100
improving · +5.6 vs previous 14 d
Energy level
Daily log2.3/10
improving · +0.8 vs previous 14 d
Stress level
Daily log6.2/10
improving · -0.4 vs previous 14 d
Steps
Wearable2,507
stable · -19 vs previous 14 d
Adherence
Companion45.4 %
worsening · -4.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 23 from the failing basin, 67 from restoration.
Would help
Would not help
- Keep fat lowGI +4.7 next day on high-intake days · n 19
- Keep histamine lowGI +3.6 next day on high-intake days · n 20
- Keep simple carbs lowGI +3.2 next day on high-intake days · n 19
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+4.7detractor · 95%
- Histamine load+3.6detractor · 95%
- Simple carbohydrates+3.2detractor · 89%
- Insoluble fibre+2.5detractor · 71%
- Spicy / capsaicin+1.6no signal · 39%
- Alcohol+0.6no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 56 and rising
- WearableSleep 5.6 h, below personal baseline
- Autonomic recovery ↓65
- WearableResting HR 83 bpm
- Wearable2,507 steps/day
- WearableShort sleep window
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 34/100
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 44
- Inflammatory signalling ↓45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 51
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 34/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 38 ms
- Sleep
- 5.6 h
- Steps
- 1,902
- Resting HR
- 82 bpm
Daily log: GI score 56, nutritional resilience 41, adherence 45.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01699 | 23% | S04 | GI-04 | improved | 69 |
| P-01509 | 20% | S17 | — | — | 68 |
| P-01877 | 23% | S01 | CR-01 | improved | 67 |
| P-01629 | 20% | S19 | — | — | 66 |
| P-01714 | 24% | S14 | GI-04 | improved | 66 |
| P-01858 | 30% | S14 | NP-02 | improved | 65 |
| P-01317 | 20% | S19 | — | — | 65 |
| P-01643 | 20% | S17 | — | — | 65 |
| P-01417 | 29% | S14 | GI-04 | improved | 65 |
| P-01511 | 29% | S14 | GI-04 | improved | 65 |
| P-01527 | 20% | S17 | — | — | 65 |
| P-01660 | 21% | S19 | — | — | 64 |